N ODonovan
Overview
Explore the profile of N ODonovan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Caiazza F, McGowan P, Mullooly M, Murray A, Synnott N, ODonovan N, et al.
Br J Cancer
. 2025 Mar;
PMID: 40087384
No abstract available.
2.
Eustace A, Madden S, Fay J, Collins D, Kay E, Sheehan K, et al.
Breast Cancer Res Treat
. 2021 May;
187(3):635-645.
PMID: 33983492
Background: Pre-treatment tumour-associated lymphocytes (TILs) and stromal lymphocytes (SLs) are independent predictive markers of future pathological complete response (pCR) in HER2-positive breast cancer. Whilst studies have correlated baseline lymphocyte levels...
3.
Synnott N, Murray A, McGowan P, Kiely M, Kiely P, ODonovan N, et al.
Int J Cancer
. 2016 Sep;
140(1):234-246.
PMID: 27615392
The identification and validation of a targeted therapy for patients with triple-negative breast cancer (TNBC) is currently one of the most urgent needs in breast cancer therapeutics. One of the...
4.
Mahgoub T, Eustace A, Collins D, Walsh N, ODonovan N, Crown J
Int J Oncol
. 2015 Jul;
47(3):900-8.
PMID: 26201960
Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective of the present study was to identify novel therapeutic targets for metastatic melanoma. A...
5.
Caiazza F, McGowan P, Mullooly M, Murray A, Synnott N, ODonovan N, et al.
Br J Cancer
. 2015 May;
112(12):1895-903.
PMID: 26010411
Background: Identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), that is, breast cancers negative for oestrogen receptors, progesterone receptors and HER2 amplification, is currently one of...
6.
Casserly P, Harrison M, OConnell O, ODonovan N, Plant B, OSullivan P
Eur Arch Otorhinolaryngol
. 2014 Dec;
272(11):3353-9.
PMID: 25537816
Cystic fibrosis (CF) is a common inherited disorder in Caucasians in Ireland having the highest reported incidence. CF has well-recognised clinical sequelae in several physiological systems. Its' impact on the...
7.
Lane G, Dunne C, English A, Finucane P, OConnor R, Griffin M, et al.
Ir Med J
. 2014 Mar;
107(2):55-7.
PMID: 24654489
Increased care provision and clinical activity in General Practice in Ireland will have important manpower implications. Recent developments in medical education policy including the introduction of graduate-entry medical degree programmes...
8.
McGowan P, Mullooly M, Caiazza F, Sukor S, Madden S, Maguire A, et al.
Ann Oncol
. 2012 Sep;
24(2):362-369.
PMID: 22967992
Background: Validated targeted therapy is currently unavailable for patients with invasive breast cancer negative for oestrogen receptors, progesterone receptors and HER2 [i.e., those with triple-negative (TN) disease]. ADAM-17 is a...
9.
Collins D, ODonovan N, McGowan P, OSullivan F, Duffy M, Crown J
Ann Oncol
. 2011 Nov;
23(7):1788-95.
PMID: 22056974
Background: Antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by CD56+natural killer (NK) cells may contribute to the activity of trastuzumab in HER-2-amplified tumours. In this study, we investigated the possibility that trastuzumab...
10.
Tryfonopoulos D, Walsh S, Collins D, Flanagan L, Quinn C, Corkery B, et al.
Ann Oncol
. 2011 Mar;
22(10):2234-40.
PMID: 21357651
Background: Triple-negative breast cancers lack expression of estrogen and progesterone receptors and overexpression of human epidermal growth factor receptor 2 (HER2). Unlike other subgroups of patients with breast cancer, targeted...